WUXI APPTEC - VOLUNTARY ANNOUNCEMENT

WUXI APPTEC CO., LTD.*

無錫藥明康德新藥開發股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2359)

VOLUNTARY ANNOUNCEMENT

This announcement is made by WuXi AppTec Co., Ltd.* (無錫藥明康德新藥開發股份有限公司) (the "Company" or "WuXi AppTec") on a voluntary basis.

The Company notes that on June 8, 2026 (United States time), the United States Department of Defense incorrectly included WuXi AppTec in its updated Section 1260H list of designated "Chinese military companies". We believe that the designation of WuXi AppTec on this updated list, along with the alleged basis for the designation, was clearly a mistake, and WuXi AppTec will take immediate actions to challenge and correct this erroneous designation.

WuXi AppTec does not meet the statutory criteria for designation as a "Chinese military company." The allegation basis for our 1260H list designation is factually incorrect given that: (i) we are not owned or controlled by or affiliated with any military or government entity of the People's Republic of China (the "PRC"); (ii) we do not provide services to the PRC military; and (iii) we are not associated with the PRC's defense industrial base or military-civil fusion programs.

WuXi AppTec is an independent, publicly traded company serving thousands of partners across over 30 countries to develop life-saving medicines for global patients. We have earned the trust of customers for over 25 years through our commitment to excellence, security, and innovation. The integrity of our global operations is demonstrated by our track record, including more than 50 successful inspections by the United States, the European Union, and other regulators in 2025 alone, along with hundreds of customer audits.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board

WuXi AppTec Co., Ltd.* Dr. Ge Li

Chairman

Hong Kong, June 9, 2026

As of the date of this announcement, the Board comprises Dr. Ge Li, Dr. Minzhang Chen, Dr. Steve Qing Yang and Mr. Zhaohui Zhang as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Ms. Christine Shaohua Lu-Wong, Dr. Wei Yu, Dr. Xin Zhang, Ms. Zhiling Zhan and Mr. Xuesong Leng as independent non-executive Directors.

• For identification purposes only